Methods and Compositions for Treating Vasomotor Symptoms
AssigneeUniversity of Washington through its Center for Commercialization
InventorsRobert A. STEINER, Charles CHAVKIN, Donald K. CLIFTON, Susan REED, Victor NAVARRO
Life of this patent
Estimating the term…
Abstract
The present disclosure is generally directed to compositions and methods for treating or limiting development of vasomotor symptoms in a subject.
Claims16
A method for treating or limiting development of vasomotor symptoms (VMS), comprising administering to a subject in need thereof an amount effective to treat or limit development of VMS of a compound that inhibits kisspeptin/neurokinin B/dynorphin (KNDy) neurons.
A method for treating or limiting development of VMS, comprising administering to a subject in need thereof an amount effective to treat or limit development of VMS of a compound selected from the group consisting of a kappa agonist, an NK3R antagonist, an NK1R antagonist, combinations thereof, and pharmaceutically acceptable salts thereof.
The method of 1, wherein treating or limiting development of VMS comprises decreasing or limiting development of one or more of flushing of the skin, sweating, palpitations, racing heart rate, shivering, intermittent feeling of being too hot (hot flashes) or too cold (chills/shivering), irritability, anxiety, mood disorders, and depression, in the subject.
A pharmaceutical composition, comprising:
- (1) two or more of a kappa agonist, an NK3R antagonist, an NK1R antagonist, or salts thereof;
- and
- (2) a pharmaceutically acceptable carrier.
16-19. (canceled)
Dependencies are inferred from the claim text.